Last updated: September 7, 2026
Caffeine citrate is a mature neonatal medicine used primarily to treat apnea of prematurity. Its commercial profile is defined by stable clinical demand, limited product differentiation, generic competition, and manufacturing sensitivity for sterile injectable products. The original branded product, Cafcit, no longer has meaningful market exclusivity. Revenue data are not disclosed at the product level, but caffeine citrate remains strategically relevant because neonatal intensive-care units require dependable supply and have limited therapeutic substitutes.
What is caffeine citrate and how is it used?
Caffeine citrate is the citrate salt of caffeine. It is administered to premature infants to reduce apnea of prematurity, a condition associated with immature respiratory control. The FDA-approved labeling covers both oral solution and intravenous injection formulations. A 20 mg dose of caffeine citrate corresponds to 10 mg of caffeine base. [1]
| Attribute |
Caffeine citrate |
| Active ingredient |
Caffeine citrate |
| Primary indication |
Short-term treatment of apnea of prematurity |
| Main patient population |
Premature neonates |
| Common strength |
20 mg/mL caffeine citrate, equivalent to 10 mg/mL caffeine base |
| Dosage forms |
Oral solution and sterile injection |
| FDA pathway |
New drug application and abbreviated new drug applications |
| Primary care setting |
Neonatal intensive-care units |
| Reference product |
Cafcit |
| Biosimilar exposure |
None; caffeine citrate is a small molecule |
| Main commercial risk |
Generic price erosion and sterile supply disruption |
The product is typically used after exclusion of other causes of apnea, including infection, metabolic disorders, anemia, and airway obstruction. Treatment duration varies with gestational age, clinical response, and institutional practice.
What is the FDA and Orange Book status of caffeine citrate?
Cafcit was approved by the FDA under NDA 020793. The product was originally marketed by Roxane Laboratories and is now associated with Chiesi USA in the U.S. market. FDA labeling identifies caffeine citrate injection and oral solution as prescription products for apnea of prematurity. [1,2]
The original approval included pediatric exclusivity activity, but that period expired many years ago. Caffeine citrate is now a mature generic market. The Orange Book does not provide the type of active patent barrier associated with newer specialty medicines, and the reference product has no commercially meaningful remaining exclusivity based on the original approval. [2]
| Regulatory element |
Status |
| Reference NDA |
NDA 020793 |
| Reference product |
Cafcit |
| Active ingredient |
Caffeine citrate |
| Pediatric indication |
Apnea of prematurity |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Expired |
| Orphan-drug-style commercial exclusivity |
Not the principal barrier |
| Current regulatory model |
Brand plus generic competition |
| Orange Book relevance |
Product identification and therapeutic-equivalence framework rather than active patent protection |
Caffeine citrate’s regulatory value lies in established labeling and neonatal use, not in current exclusivity.
When does caffeine citrate lose exclusivity?
Caffeine citrate lost practical market exclusivity long before the current market period. The reference product was approved in 1999, and any five-year new chemical entity exclusivity and six-month pediatric extension have expired. [2,3]
The market therefore operates under the standard generic framework. A manufacturer can seek approval through an ANDA if it demonstrates pharmaceutical equivalence, bioequivalence where applicable, manufacturing compliance, and suitable quality controls.
What patent protection covers Cafcit?
The principal commercial protection for Cafcit was regulatory approval and product familiarity rather than a durable patent estate. No active, high-value Orange Book patent portfolio is associated with the product in the way seen for modern branded medicines with formulation, device, or method-of-use patents.
Potential patent categories for caffeine citrate include:
- Composition and salt-form patents
- Oral-solution formulation patents
- Sterile injectable formulation patents
- Container-closure and packaging patents
- Manufacturing-process patents
- Method-of-use patents for neonatal respiratory disorders
These categories do not appear to create a meaningful market-wide barrier for current U.S. generic entry. Process and manufacturing patents, if any remain in force, would generally affect a specific manufacturing route rather than block all competing products.
How many companies compete in the caffeine citrate market?
Competition is divided between the branded reference product and generic manufacturers. Product availability can vary by formulation, strength, package size, and hospital contract.
The principal commercial participants have included:
| Company |
Market role |
Relevant capability |
| Chiesi USA |
Reference-brand supplier associated with Cafcit |
Branded neonatal product and specialty hospital distribution |
| Hikma Pharmaceuticals |
Generic and injectable manufacturer |
Sterile injectable and hospital generic infrastructure |
| Other ANDA holders |
Generic supply |
Oral solution and/or injection supply subject to FDA approval and commercial launch |
| Hospital distributors |
Channel participants |
Formulary, inventory, and neonatal-unit distribution |
The number of approved ANDA holders is not equivalent to the number of active suppliers. Some companies maintain approval without continuous commercial distribution. Hospital purchasing contracts, shortage conditions, and manufacturing capacity determine effective competition.
What formulations are protected by caffeine citrate patents?
The two commercially important formulations are oral solution and sterile injection.
Oral solution
The oral solution is relatively simple from a formulation perspective. Its commercial advantages include ease of dosing, suitability for enteral administration, and lower manufacturing complexity than a sterile injectable. Formulation differentiation may involve:
- Concentration and dose-volume design
- pH control
- Preservative system
- Container-closure configuration
- Stability and storage conditions
- Unit-dose packaging
These characteristics can support product quality or marketing differentiation, but they generally do not create a durable barrier to ANDA competition.
Sterile injection
The injectable product has greater manufacturing complexity because it requires sterile compounding, aseptic filling, validated container closure, particulate control, and reliable supply of hospital-ready vials. Those requirements create a stronger operational barrier than the underlying molecule creates a legal barrier.
Sterile manufacturing failures, facility inspections, component shortages, and quality-system remediation can reduce effective supply even when several approvals exist. For this reason, injectable caffeine citrate may show more pricing resilience than oral solution in periods of constrained supply.
Are there Paragraph IV challenges or caffeine citrate patent lawsuits?
Caffeine citrate has limited current Paragraph IV litigation risk because the major exclusivity period has expired and the reference product does not present a significant active patent barrier.
A Paragraph IV certification would be relevant only if an ANDA applicant challenged a listed patent as invalid, unenforceable, or not infringed. Based on the mature status of Cafcit and the absence of a prominent active Orange Book patent estate, caffeine citrate is not a major current Paragraph IV litigation market.
No major, publicly prominent settlement agreement involving a current Cafcit patent barrier is central to U.S. market access. The more important commercial disputes are likely to concern supply contracts, product quality, shortages, and purchasing terms rather than patent validity.
What is the competitive landscape for caffeine citrate?
The market has four structural characteristics.
First, clinical demand is relatively inelastic. Hospitals cannot easily eliminate caffeine therapy for eligible premature infants because it is integrated into neonatal respiratory management.
Second, the addressable population is limited. Demand is linked to premature births and the proportion of infants treated for apnea of prematurity. The World Health Organization estimated 13.4 million preterm births globally in 2020, representing approximately one in 10 live births. [4]
Third, product switching is easier for hospitals when formulations are therapeutically equivalent and supply is reliable. This increases generic price pressure.
Fourth, sterile injectable capacity can matter more than patent ownership. A supplier with an approved product but weak manufacturing reliability may have less commercial influence than a smaller supplier with dependable hospital inventory.
How does caffeine citrate compare with competing neonatal therapies?
| Therapy |
Role in apnea of prematurity |
Commercial relationship |
| Caffeine citrate |
Standard pharmacologic treatment |
Primary market |
| Caffeine base |
Same active pharmacology, different salt presentation |
Usually not a separate clinical substitute in procurement |
| Theophylline |
Older methylxanthine alternative |
Less favored because of narrower therapeutic window and monitoring burden |
| Respiratory support |
Non-drug management |
Complementary rather than direct pharmaceutical competition |
Caffeine citrate has displaced much of the historical role of theophylline because caffeine has a longer half-life, simpler dosing, and a wider practical therapeutic margin in premature infants. [5]
What is the financial trajectory for caffeine citrate?
Caffeine citrate is a mature, low-growth pharmaceutical asset. Its financial trajectory is best characterized as stable unit demand with declining or pressured pricing, interrupted by supply-driven volume opportunities.
| Financial driver |
Expected effect |
| Preterm birth volume |
Supports baseline demand |
| Generic entry |
Reduces average selling price |
| Hospital contracting |
Increases purchasing pressure |
| Sterile injectable shortages |
Can temporarily improve pricing and volumes for available suppliers |
| Brand loyalty |
Limited once generic products are established |
| Neonatal clinical necessity |
Protects demand from major volume collapse |
| Product-level disclosure |
Limited, because suppliers generally report broader business segments |
Chiesi and other private or diversified manufacturers do not generally disclose product-level caffeine citrate revenue. Hikma reports broad business segments rather than a separate caffeine citrate revenue line. As a result, public filings do not support a reliable standalone estimate of global caffeine citrate sales. [6,7]
The economic value is concentrated in manufacturing efficiency, hospital access, and supply reliability. A branded price premium can persist in some institutions where formulary managers prioritize continuity of supply, packaging convenience, or established vendor relationships. That premium is constrained by generic alternatives.
What generic launch scenarios exist for caffeine citrate?
Base case: continued generic erosion
The most likely scenario is stable neonatal demand with gradual price erosion. Oral solution faces the greatest commoditization risk because manufacturing is comparatively straightforward and switching costs are low.
Upside case: sterile supply disruption
A manufacturing interruption by one or more injectable suppliers could shift volume to remaining manufacturers. This may increase short-term sales and improve contract leverage, but it would not create durable exclusivity.
Downside case: concentrated procurement
Large hospital systems and group purchasing organizations may consolidate purchasing around a small number of suppliers. This can reduce supplier margins and make regulatory compliance, inventory management, and contract performance decisive.
Limited risk case: therapeutic substitution
Substitution with theophylline is possible but clinically less attractive. Nonpharmacologic respiratory support is complementary and does not eliminate the pharmaceutical market. The principal threat is therefore price competition, not replacement by a superior drug.
What manufacturing and geographic barriers affect caffeine citrate?
Caffeine citrate has broad global clinical use, but regulatory and commercial conditions differ by region.
In the United States, the main barriers are FDA approval, current Good Manufacturing Practice compliance, sterile-facility capacity, and hospital contracting. In Europe, suppliers must meet European Medicines Agency or national authorization requirements, pharmacopoeial standards, and local procurement rules. Emerging markets may have lower product prices but greater variability in reimbursement, registration, distribution, and hospital purchasing.
Geographic expansion is easier for oral solution than for sterile injection, but neonatal products require strong pharmacovigilance, precise dosing information, and reliable pediatric packaging in every jurisdiction.
What is the investment and licensing outlook for caffeine citrate?
Caffeine citrate is unlikely to attract licensing interest as a stand-alone discovery asset. Its value is more relevant to:
- Generic injectable portfolios
- Neonatal hospital-product platforms
- Contract manufacturing relationships
- Specialty pharmaceutical distributors
- Supply agreements with neonatal intensive-care networks
A licensing transaction would most likely involve geographic rights, commercial distribution, or manufacturing capacity rather than patent rights to the molecule.
Key Takeaways
- Caffeine citrate is a mature neonatal medicine with stable underlying demand.
- Cafcit’s original exclusivity has expired, and current U.S. market access is primarily generic.
- The product has no meaningful biosimilar risk because it is a small molecule.
- Oral solution is more exposed to price competition than sterile injection.
- Injectable manufacturing reliability is the strongest practical competitive barrier.
- Paragraph IV and patent-litigation risk are limited relative to newer branded drugs.
- Revenue is not disclosed at the product level by major suppliers.
- Financial performance depends on hospital contracts, generic pricing, and supply continuity.
- The most material upside is temporary volume capture during sterile injectable shortages.
- Long-term commercial value is operational rather than patent-driven.
FAQs About Caffeine Citrate Market and Patent Risk
Is caffeine citrate still under patent protection?
Caffeine citrate is not protected by the type of active, commercially significant patent estate associated with recently approved branded drugs. Its principal U.S. exclusivity periods have expired.
Is caffeine citrate a biologic or biosimilar product?
No. Caffeine citrate is a conventional small-molecule drug. FDA approval of competing products generally follows the ANDA generic pathway, not the biosimilar pathway.
Why can caffeine citrate remain profitable after patent expiry?
Demand is clinically necessary in neonatal intensive-care units, and sterile injectable supply is technically demanding. Reliable manufacturers can retain volume even after generic entry.
Is theophylline a direct substitute for caffeine citrate?
Theophylline is a pharmacologic alternative, but caffeine is generally preferred in apnea of prematurity because of dosing convenience, longer half-life, and a more favorable practical safety profile.
What is the largest commercial risk for caffeine citrate manufacturers?
The largest risk is margin compression from generic competition, followed by sterile manufacturing interruptions, hospital purchasing concentration, and regulatory quality actions.
References
- U.S. Food and Drug Administration. (2023). Cafcit (caffeine citrate) injection and oral solution prescribing information.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Cafcit, NDA 020793.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- World Health Organization. (2023). Born too soon: Decade of action on preterm birth.
- U.S. Food and Drug Administration. (2023). Caffeine citrate labeling and clinical pharmacology information.
- Chiesi Farmaceutici S.p.A. (2023). Annual report and financial disclosures.
- Hikma Pharmaceuticals PLC. (2023). Annual report and accounts.
